Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

Open access
Gertz, Morie A., Scheinberg, Morton, Waddington-Cruz, Márcia, Heitner, Stephen B., Karam, Chafic, Drachman, Brian, Khella, Sami, Whelan, Carol, Obici, Laura · 2019 · Expert Review of Clinical Pharmacology

Abstract

Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body.Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance.Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17512433.2019.1635008

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 7

  1. Coelho T, 2016, A guide to transthyretin amyloidosis
  2. Gertz MA., 2017, Am J Manag Care, 23, S107
  3. 2018, Vyndaqel [summary of product characteristics]
  4. 2019, Vyndaqel [prescribing information]
  5. 2018, Tegsedi [prescribing information]
  6. 2018, Tegsedi [summary of product characteristics]
  7. Brannagan T, 2018, Presented at: American Society of Hematology Annual Meeting and Exposition

Cited by

See all 38

Metadata

Authors
Gertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L.
Affiliations
  • Mayo Clinic (US)
  • Hospital Israelita Albert Einstein (BR)
  • Neuromuscular Diseases Unit, Federal University of Rio de Janeiro, University Hospital, Rio de Janeiro, Brazil
  • Oregon Health & Science University (US)
  • University of Pennsylvania (US)
  • University College London (GB)
  • Policlinico San Matteo Fondazione (IT)
Corresponding author
Gertz, Morie A.
Venue
Expert Review of Clinical Pharmacology
Published
2019-07-03
Volume
12
Issue
8
Pages
701-711
ISSN
  • 1751-2433 (ISSN-L)
  • 1751-2441
OpenAlex
W2955523092
Cited by
38
References
50
Citations by year
2026: 2 · 2025: 1 · 2024: 8 · 2023: 9 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 1
FWCI
1.49
Type
journal article
Language
en
Open access
Locations
  • Expert Review of Clinical Pharmacology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders
ApotheCom (01)
Topics
  • Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
inotersen, hereditary transthyretin amyloidosis, polyneuropathy, antisense oligonucleotides, familial amyloid cardiomyopathy, glomerulonephritis, thrombocytopenia, drug safety and tolerability
MeSH terms
Adult, Animals, Humans, Mutation, Oligonucleotides, Polyneuropathies, Prealbumin, Quality of Life, Oligodeoxyribonucleotides, Antisense, Amyloid Neuropathies, Familial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. https://app.cochat.ai/papers/10.1080/17512433.2019.1635008
The paper
Gertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L. (2019). Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2019.1635008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.